Summary
In the mid of 1990s, patents related to prostratin from mamala plant were issued by US Army, the National Institute of Health (US) and Brigham Young University without apparent agreement with any of Samoan authority. Research afterward found that prostratin might have anti-HIV properties which were not related to the scope of existing patents. National Cancer Institute then licensed AIDS Research Alliance (ARA) to conduct human testing of prostratin as HIV/AIDS treatment. In 2001, ARA made agreement with Samoa Government to share 20 % of any future royalties from medication developed. The detail about the case study can be obtained from the following link:
